首页|肿瘤相关中性粒细胞和中性粒细胞与淋巴细胞比值对乳腺癌新辅助化疗疗效及预后的评估价值

肿瘤相关中性粒细胞和中性粒细胞与淋巴细胞比值对乳腺癌新辅助化疗疗效及预后的评估价值

扫码查看
目的 探讨CD66b+肿瘤相关中性粒细胞(TANs)和中性粒细胞与淋巴细胞比值(NLR)对乳腺癌新辅助化疗(NACT)疗效及预后的评估价值。方法 回顾性收集2015年1月-2020年6月在连云港市第一人民医院乳腺外科接受NACT治疗的167例浸润性乳腺癌患者的乳腺癌组织,同时收集正常乳腺组织40例作为对照。采用免疫组化染色检测NACT前乳腺癌组织和正常乳腺组织中CD66b的表达情况;在NACT第1个周期前行血常规检查,计数中性粒细胞及淋巴细胞,并计算NLR。采用χ2检验分析TANs和NLR与乳腺癌患者临床病理因素的相关性;采用单因素χ2检验和多因素logistic回归分析NACT疗效的影响因素;采用Kaplan-Meier生存分析和多因素Cox回归分析乳腺癌患者预后的影响因素;采用Spearman检验分析TANs与NLR的相关性。结果 CD66b在乳腺癌组织中的表达明显高于正常乳腺组织(P<0。001),且弥漫性分布于肿瘤各处(癌巢和间质均可见浸润)。NACT前癌巢高浸润TANs与高临床分期、淋巴结转移和复发转移密切相关(P<0。05);NACT前外周血高NLR与高cT分期和复发转移密切相关(P<0。05)。NACT前外周血NLR(P=0。007)、cT分期(P=0。041)、雌激素受体(ER)状态(P=0。009)和人表皮生长因子受体2(HER2)表达(P=0。020)是浸润性乳腺癌患者病理完全缓解(pCR)的独立预测因素。NACT前癌巢TANs(P=0。023)、高临床分期(P=0。040)、pCR(P=0。027)是影响浸润性乳腺癌患者无病生存期(DFS)的独立危险因素。NLR与TANs相关性不明显(r=0。14,P=0。071)。结论 NACT前癌巢内低浸润TANs预示乳腺癌患者预后更好;外周血高NLR与化疗耐药相关。
The value of tumor associated neutrophils and neutrophil to lymphocyte ratio in evaluating the efficacy and prognosis of neoadjuvant chemotherapy for breast cancer
Objective To investigate the value of CD66b+tumor-associated neutrophils(TANs)and neutrophil to lymphocyte ratio(NLR)in evaluating the efficacy and prognosis of neoadjuvant chemotherapy(NACT)for breast cancer.Methods One hundred and sixty-seven patients of invasive breast cancer treated with NACT in the Department of Breast Surgery,the First People Hospital of Lianyungang from January 2015 to June 2020 were collected,and 40 cases of normal breast tissues were collected.Immunohistochemistry was used to detect the expression of CD66b in breast cancer tissues before NACT and normal breast tissues.Peripheral venous blood was taken from patients within 1 week before the first cycle of NACT,count neutrophils and lymphocytes were counted and their ratio(NLR)was calculated.The correlation between TANs and NLR and clinicopathologic features was analyzed by χ2 test.The influencing factors of efficacy of NACT were analyzed by univariate χ2 test and multivariate logistic analysis.Kaplan-Meier survival analysis and multivariate Cox analysis were used to determine the prognostic factors.The correlation between TANs and NLR was determined by Spearman test.Results The expression of CD66b in breast cancer tissues was significantly higher than that in normal breast tissues(P<0.05),and it was diffusely distributed throughout the tumor(cancer nest and stroma were infiltrated).High infiltration of parenchymal TANs before NACT was correlated with high clinical stage,lymph node metastasis,and recurrence and metastasis(P<0.05).High NLR before NACT was closely related to high cT stage and recurrence and metastasis(P<0.05).NLR of peripheral blood(P=0.007),cT stage(P=0.041),estrogen receptor(ER)status(P=0.009),and human epidermal growth factor 2(HER2)expression(P=0.020)were independent predictors for pathologic complete response(pCR).TANs(P=0.023),high clinical stage(P=0.040),and pCR(P=0.027)before NACT were independent risk factors for disease-free survival(DFS)of patients with invasive breast cancer.There was no correlation between NLR and TANs(r=0.14,P=0.071).Conclusions Low infiltration of parenchymal TANs before NACT predicts a better prognosis for patients with breast cancer.Higher NLR in peripheral blood is associated with chemotherapy resistance.

breast cancerneoadjuvant chemotherapytumor-associated neutrophilsneutrophil to lymphocyte ratiopathologic complete response

林佳雯、李淑琴、卫姣飞

展开 >

南京医科大学连云港临床医学院乳腺外科,江苏连云港 222000

连云港市第一人民医院乳腺外科,江苏连云港 222000

乳腺癌 新辅助化疗 肿瘤相关中性粒细胞 中性粒细胞与淋巴细胞比值 病理完全缓解

2024

解放军医学杂志
人民军医出版社

解放军医学杂志

CSTPCD北大核心
影响因子:1.644
ISSN:0577-7402
年,卷(期):2024.49(12)